A prospective study on modulation of immunosuppression for epstein-barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation

Transplantation

Volumn 89, Issue 12, 2010, Pages 1533-1540

  Cesaro, Simone ^a,b   Pegoraro, Anna ^a,b   Tridello, Gloria ^a   Calore, Elisabetta ^a   Pillon, Marta ^a   Varotto, Stefania ^a   Abate, Davide ^a   Barzon, Luisa ^a   Mengoli, Carlo ^a   Carli, Modesto ^a   Messina, Chiara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

EBV reactivation; Hematopoietic stem cell transplantation; Pediatric; Posttransplant EBV lymphoma

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954086657     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181dd6c0a     Document Type: Article

References (39)

1. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplanta- tionasaconsequence ofintensive immunosuppressive treatment.Bone Marrow Transplant 2003; 32: 97.
2. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251.
3. Buyck HC, Ball S, Junagade P, et al. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lympho-proliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009; 43: 813.
4. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatched, splenectomy, and recipient Epstein-Barr virus seronegativity as risk factors in posttransplant lymphoproliferative disorder following allo-geneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 2208.
6. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42: 181.
7. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment ofEpstein-Barr virus induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549.
8. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cy-totoxic T cells. Blood 2000; 95: 807.
9. Aalto SM, Juvonen E, Tarkkanen J, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007; 45: 1305.
10. Gärtner BC, Schäfer H, Marggraff K, et al. Evaluation of use of Epstein Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351.
11. Hoshino Y, Kimura H, Tanaka N, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogeneic stem cell transplantation. Br J Haematol 2001; 115: 105.
12. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972.
13. Cesaro S, Murrone A, Mengoli C, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the preemptive management of Epstein-Barr virus reactivation after alloge-neic haematopoietic stem cell transplantation.BrJHaematol 2005; 128: 224.
14. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364.
15. Gruhn B, Meerbach A, Hafer R, et al. Pre-emptive therapy with ritux-imab for prevention of Epstein-Barr virus-associated lymphoprolifera-tive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31: 1023.
16. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol He-matol 2005; 56: 155.
17. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002.
18. Biasolo MA, Calistri A, Cesaro S, et al. Case report: Kinetics of Epstein-Barr virus load in a bone marrow transplant patient with no sign of lymphoproliferative disease. J Med Virol 2003; 69: 220.
19. Bearman SI, Appelbaum FR, Back A, et al. Regimen-related toxicity and early posttransplant survivalinpatients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989; 7: 1288.
20. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42.
21. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255.
22. Farag SS. Chronic graft versus host disease: Where do we go from here? Bone Marrow Transplant 2004; 33: 569.
23. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (ritux-imab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502.
24. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552.
25. Styczynski J, ReusserP, EinseleH, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757.
26. Clave E, Ablika F, Bajzik V, et al. Epstein-Barr virus reactivation in allogeneic stem cell transplantation: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76.
27. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and non-malignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611.
28. Rocha V, Labopin M, Sanz G, et al. Transplantsofumbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276.
29. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009; 87: 1240.
30. Corti P, Peters C, Balduzzi A, et al. Reconstitution of lymphocyte sub-populations in children with inherited metabolic storage diseases after haematopoietic cell transplantation. Br J Haematol 2005; 130: 249.
31. Buser A, Stern M, Arber C, et al. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: An effectofpretreat-ment with rituximab? Bone Marrow Transplant 2008; 42: 483.
32. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy\Rare but there! Leuk Lymphoma 2009; 50: 1083.
33. Aksoy S, Dizdar O, Hayran M, et al. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: A systematic review and meta-analysis. Leuk Lymphoma 2009; 50: 357.
34. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoen-cephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: Case report and reviewof the literature. Clin Neuropathol 2007; 26: 68.
35. Qazilbash MH, Qu Z, Hosing C, et al. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol 2005; 80: 43.
36. Faye A, Quartier P, Reguerre Y, et al. Chimeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation. Br J Haematol 2001; 115: 112.
37. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: The role of rituximab. Transpl Int 2006; 19: 259.
38. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell recon-stitution. Clin Infect Dis 2006; 42: 1743.
39. Uhlin M, Okas M, Gertow J, et al. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010; 59: 473.